Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
Guardant Health (GH) Stock Price & Analysis
1,759 Followers
GH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.81 - $41.06
Previous Close$28.26
Volume715.02K
Average Volume (3M)2.25M
Market Cap
$3.46B
Enterprise Value$4.78B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Aug 01, 2024EPS Estimate
-$0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.92
Shares Outstanding122,369,214
10 Day Avg. Volume1,838,526
30 Day Avg. Volume2,254,267
Standard Deviation0.17
R-Squared0.13
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)63.79
Price to Sales (P/S)23.33
Price to Cash Flow (P/CF)-29.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.91
Enterprise Value/Gross Profit14.18
Enterprise Value/Ebitda-9.06
Forecast
1Y Price Target
$37.23Price Target Upside28.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Guardant Health News
Bulls Say, Bears Say
Bulls Say
FDA ApprovalFDA approval remains the key catalyst, and management expects coverage and guideline inclusion thereafter.
Market PotentialShield appears to gain first line approval, and the $20B CRC screening will likely be multi-modal, with Shield capturing a meaningful portion of the market.
Safety And EffectivenessThe FDA AdCom panel voted that the benefits of Shield in CRC detection outweigh the risks, paving the way for likely 1st line FDA approval in CRC detection.
Bears Say
Financial ImpactWith the PCP sales force expected to be a significant source of cash burn for GH, investors will be focused on what the AdCom portends for Shield’s LT opportunity and if the cash burn is warranted.
Product PerformanceShield does not appear to be appropriate for first-line screening or for advanced adenoma (AA) detection.
Regulatory ConcernsThe proposed label could include a warning about limited AA detection - as GH's view that Shield has limited ability for the detection of advanced adenomas.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $15.81 and its highest was $41.06 in the past 12 months.
What is Guardant Health’s market cap?
Currently, no data Available
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Aug 01, 2024 which is in 29 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on May 09, 2024. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.872 by -$0.068.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -$0.74.
How many shares outstanding does Guardant Health have?
Guardant Health has 122,369,220 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.872. Following the earnings report the stock price went up 15.072%.
Which hedge fund is a major shareholder of Guardant Health?
Among the largest hedge funds holding Guardant Health’s share is Deerfield Management Company, LP. It holds Guardant Health’s shares valued at 16M.
---
Guardant Health Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.23 (28.96% Upside)
$37.23 (28.96% Upside)
Blogger Sentiment
Bullish
GH Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 66.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 10.3%
Last 30 Days ▲ 10.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.06%
12-Months-Change
Fundamentals
Return on Equity
-3883.89%
Trailing 12-Months
Asset Growth
12.77%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
---
GH Company Deck
---
GH Earnings Call
Q1 2024
0:00 / 0:00
---
GH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
---
GH Stock 12 Month Forecast
Average Price Target
$37.23
▲(28.96% Upside)
Technical Analysis
Best Analysts Covering GH
1 Year
1 Year Success Rate
9/10 ratings generated profit
1 Year Average Return
+24.53%
assigned a buy rating 2 months ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +24.53% per trade.
---